U24DK130164
Cooperative Agreement
Overview
Grant Description
Liver Cirrhosis Network: Scientific and Data Coordination Center - Project Summary
Liver cirrhosis poses a significant public health burden in the United States (US) as it is associated with substantial morbidity, mortality, and cost. An estimated one-third of patients develop decompensating events such as gastrointestinal variceal bleeding, ascites, hepatic encephalopathy (HE), jaundice, and renal impairment. Furthermore, these poor outcomes are also associated with the development of hepatocellular carcinoma (HCC) in the cirrhotic liver, the ninth leading cause of death among cancers within the US.
While transplantation is a curative treatment for cirrhosis, patients are often ineligible for transplantation due to the lack of available organs and additional risks involved. Thus, patients and providers frequently focus on symptomatic treatment options such as lifestyle/nutrition modifications to initiate weight loss and optimize protein absorption, nonselective beta-blockers to reduce the risk of gastrointestinal bleeding, and treatment for HE to improve confusion.
A recent meta-analysis suggests statin therapy as a promising treatment for cirrhosis as statins tend to decrease oxidative stress and inflammation and increase endothelial cell function, with downstream effects including the reduction of hepatic inflammation, fibrosis, and vascular tone. Although this review represents over 120 thousand patients, true efficacy data in the setting of a randomized controlled trial (RCT) are presently limited to just four RCTs from outside of the US, representing less than 300 patients with cirrhosis.
To better understand the natural history of the disease and also to further evaluate the use of statins in the treatment of cirrhosis, the Liver Cirrhosis Network (LCN), consisting of up to 10 clinical centers (CCs) and one Scientific and Data Coordination Center (SDCC), will be charged with developing (a) a prospective cohort and (b) an RCT to evaluate statin efficacy in patients with cirrhosis.
Northwestern University Data Analysis and Coordinating Center (NUDACC) and its partners propose to serve as the SDCC - the central scientific and leadership core for the LCN - coordinating all operational and data-related activities using cutting-edge resources for study design, planning and conduct, ongoing monitoring, and statistical analyses. NUDACC unites an interdisciplinary team with wide-ranging experience including collaborative and methodologic biostatisticians, hepatologists, data managers, project managers, and multiple supporting study staff.
Together, we propose to collaborate with the LCN to lead the design, conduct, coordination, oversight, management, administration, analyses, and dissemination for the LCN-related studies.
Liver cirrhosis poses a significant public health burden in the United States (US) as it is associated with substantial morbidity, mortality, and cost. An estimated one-third of patients develop decompensating events such as gastrointestinal variceal bleeding, ascites, hepatic encephalopathy (HE), jaundice, and renal impairment. Furthermore, these poor outcomes are also associated with the development of hepatocellular carcinoma (HCC) in the cirrhotic liver, the ninth leading cause of death among cancers within the US.
While transplantation is a curative treatment for cirrhosis, patients are often ineligible for transplantation due to the lack of available organs and additional risks involved. Thus, patients and providers frequently focus on symptomatic treatment options such as lifestyle/nutrition modifications to initiate weight loss and optimize protein absorption, nonselective beta-blockers to reduce the risk of gastrointestinal bleeding, and treatment for HE to improve confusion.
A recent meta-analysis suggests statin therapy as a promising treatment for cirrhosis as statins tend to decrease oxidative stress and inflammation and increase endothelial cell function, with downstream effects including the reduction of hepatic inflammation, fibrosis, and vascular tone. Although this review represents over 120 thousand patients, true efficacy data in the setting of a randomized controlled trial (RCT) are presently limited to just four RCTs from outside of the US, representing less than 300 patients with cirrhosis.
To better understand the natural history of the disease and also to further evaluate the use of statins in the treatment of cirrhosis, the Liver Cirrhosis Network (LCN), consisting of up to 10 clinical centers (CCs) and one Scientific and Data Coordination Center (SDCC), will be charged with developing (a) a prospective cohort and (b) an RCT to evaluate statin efficacy in patients with cirrhosis.
Northwestern University Data Analysis and Coordinating Center (NUDACC) and its partners propose to serve as the SDCC - the central scientific and leadership core for the LCN - coordinating all operational and data-related activities using cutting-edge resources for study design, planning and conduct, ongoing monitoring, and statistical analyses. NUDACC unites an interdisciplinary team with wide-ranging experience including collaborative and methodologic biostatisticians, hepatologists, data managers, project managers, and multiple supporting study staff.
Together, we propose to collaborate with the LCN to lead the design, conduct, coordination, oversight, management, administration, analyses, and dissemination for the LCN-related studies.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Chicago,
Illinois
606114546
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 07/31/26 to 07/31/27 and the total obligations have increased 437% from $2,390,000 to $12,841,373.
Northwestern University was awarded
Liver Cirrhosis Network: Scientific and Data Coordination Center
Cooperative Agreement U24DK130164
worth $12,841,373
from the National Institute of Diabetes and Digestive and Kidney Diseases in August 2021 with work to be completed primarily in Chicago Illinois United States.
The grant
has a duration of 6 years and
was awarded through assistance program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
The Cooperative Agreement was awarded through grant opportunity Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/4/26
Period of Performance
8/28/21
Start Date
7/31/27
End Date
Funding Split
$12.8M
Federal Obligation
$0.0
Non-Federal Obligation
$12.8M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U24DK130164
Transaction History
Modifications to U24DK130164
Additional Detail
Award ID FAIN
U24DK130164
SAI Number
U24DK130164-2673300673
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NK00 NIH National Institute of Diabetes and Digestive and Kidney Diseases
Funding Office
75NK00 NIH National Institute of Diabetes and Digestive and Kidney Diseases
Awardee UEI
KG76WYENL5K1
Awardee CAGE
01725
Performance District
IL-05
Senators
Richard Durbin
Tammy Duckworth
Tammy Duckworth
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Health and Human Services (075-0884) | Health research and training | Grants, subsidies, and contributions (41.0) | $4,161,374 | 100% |
Modified: 9/4/26